Catalyst Pharmaceuticals, Inc.CPRX
NASDAQ • Healthcare
$31.16
P/E
17.31
PEG
1.41
FCF Yield
—
Rev Growth YoY
+5.6% YoY
Gross Margin
83.8%
Health Score
8/10
D/E Ratio
—
Confidence
—
Business Snapshot
Catalyst Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for rare neurological diseases, with its primary revenue driver being Firdapse for Lambert-Eaton myasthenic syndrome (LEMS). It operates in the niche rare disease market as a commercial-stage player with an approved product and a strong competitive position. With trailing twelve-month revenue of $596.96M, the company is a mid-cap revenue scale biotech. A defining characteristic is its cash-generative, debt-free business model, which provides significant financial flexibility.
Financial Health
Catalyst reports a gross margin of 83.8%, up from 82.9% in the prior year, and a net margin of 36.4%, indicating strong pricing power and operational efficiency. The balance sheet is fortress-like with a debt/equity ratio of 0.0x and a current ratio of 6.08x, well above the 1.0x threshold for liquidity safety...
Risk Assessment
- REVENUE DECELERATION — While annual revenue growth was +5.6% YoY, the most recent quarter saw a -2.1% QoQ decline, signaling a near-term slowdown.
- VALUATION DIVERGENCE — The FMP DCF fair value of $144.79 suggests a large undervaluation, but the absence of a Python DCF estimate creates uncertainty around the reliability of that single model.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- 52-WEEK POSITION — The current price of $31.16 is $1.40 below the 52-week high of $32.56, indicating the stock has pulled back from its peak despite being well above the low of $19.05.
- CONCENTRATION — As a single-product company reliant on Firdapse for nearly all revenue, Catalyst faces elevated business risk if competition or regulatory changes emerge....